Allogene Therapeutics Announces Departure of Chief Financial Officer
14 Junho 2023 - 9:00AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, announced that its Chief
Financial Officer, Eric T. Schmidt, Ph.D., will step down from his
position to spend more time with his family on the East Coast. The
Company has initiated a search to fill this position. Dr. Schmidt
will remain with the Company through August 2, 2023 to support the
reporting of second quarter financials and ensure an orderly
transition.
“On behalf of the Board and the team at Allogene, I would like
to thank Eric for his lasting impact in establishing the Company as
a leader in allogeneic CAR T. He has been an integral part of what
Allogene has created and we wish only the best for Eric and his
family,” said David Chang, M.D., Ph.D., President, Chief Executive
Officer and Co-Founder of Allogene. “While we will undoubtedly miss
Eric, we are extremely excited about our next phases of growth.
We’ve presented industry-leading data demonstrating the potential
of our platform and are focused on our potentially pivotal trial
and future BLA submission in lymphoma as well as making CAR T a
reality in solid tumors.”
“It has been a privilege to serve as the CFO of Allogene over
the past five years. While being part of the Allogene team has been
an amazing professional experience, the time away from family has
presented challenges, and is perhaps the only thing that could pull
me away from the company that I believe will soon transform the
field of cell therapy,” said Dr. Schmidt. “Although I will no
longer be a part of Allogene, I will forever be inspired by the
caliber of the team, the promise of the data, and the mission to
make CAR T more accessible to patients.”
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell candidates with the goal of delivering readily available
cell therapy on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com and
follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: our next phases of growth; the
potential of our platform; our trial being potentially pivotal;
future BLA submission in lymphoma; making CAR T a reality in solid
tumors; the promise of the data; transforming the field of cell
therapy; our goals and the potential benefits of our product
candidates. Various factors may cause material differences between
Allogene’s expectations and actual results, including risks and
uncertainties related to: our product candidates are based on novel
technologies, which makes it difficult to predict the time and cost
of product candidate development and obtaining regulatory approval;
Phase 1 data from our clinical trials is limited and may change as
more patient data become available or may not be validated in any
future or advanced clinical trial; our ability to maintain
intellectual property rights necessary for the continued
development of our product candidates, including pursuant to our
license agreements; our product candidates may cause undesirable
side effects or have other properties that could halt their
clinical development, prevent their regulatory approval or limit
their commercial potential; the extent to which COVID-19 adversely
impacts our business, including our clinical trials; the extent to
which the FDA disagrees with our clinical or regulatory
plans, which could cause future delays to our clinical trials or
require additional clinical trials; we may encounter difficulties
enrolling patients in our clinical trials; we may not be able to
demonstrate the safety and efficacy of our product candidates in
our clinical trials, which could prevent or delay regulatory
approval and commercialization; challenges with manufacturing or
optimizing manufacturing of our product candidates; and our ability
to obtain additional financing to develop our products and
implement our operating plans. These and other risks are discussed
in greater detail in Allogene’s filings with the SEC, including
without limitation under the “Risk Factor” Heading in its Form 10-Q
filed for the quarter ended March 31, 2023. Any forward-looking
statements that are made in this press release speak only as of the
date of this press release. Allogene assumes no obligation to
update the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024